Why Novo Nordisk Stock Is Sinking Today

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both jumped 0.7%.

The Danish pharmaceutical giant's stock fell after it announced it was severing ties with Hims & Hers Health, as well as releasing experimental data for an obesity drug that failed to impress investors.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Hims & Hers can no longer sell weight-loss drugs

Novo Nordisk announced this morning that it is ending its partnership with Hims & Hers, which allowed the telehealth provider to sell Novo's blockbuster weight-loss drug, Wegovy.

The company said that Hims & Hers had "failed to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of 'personalization,'" alleging that, among other things, Hims & Hers produced its version of the drug using Chinese suppliers never approved by the FDA.

Novo's trial disappoints

Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients with chronic obesity lost an average of 22.7% of their body mass at 68 weeks. While that number is significant, it is less than the 25% the company has been aiming for, disappointing investors.

Despite the disappointment, I think the pharmaceutical company is still in a solid position to continue competing in the uber-lucrative weight loss drug market, although rival Eli Lilly looks to be in a better position at the moment.

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.